GlassScriptPhysician profile
Jeffrey A Naiditch
NPI 1437243789
$3,784.03
in general payments reported to CMS, 2019-2025
11 companies · $718 in 2025
The $718 reported for 2025 was more than what 80% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $799 · 2020: $264 · 2021: $534 · 2022: $384 · 2023: $366 · 2024: $718 · 2025: $718.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,802.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,802.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $1,757.38 | 2019-2025 | Biktarvy |
| Viiv Healthcare Company | $953.92 | 2019-2025 | Apretude, Dovato, Cabenuva |
| Emd Serono, INC. | $394.06 | 2019-2025 | Serostim |
| Amgen INC. | $215.41 | 2019-2020 | |
| Glaxosmithkline, LLC. | $139.20 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $116.41 | 2019-2025 | Airsupra |
| Janssen Biotech, INC. | $94.35 | 2019-2020 | |
| Napo Pharmaceuticals INC | $52.05 | 2019-2025 | Mytesi |
| Bayer Healthcare Pharmaceuticals INC. | $32.95 | 2021 | |
| Novartis Pharmaceuticals Corporation | $14.30 | 2022 | |
| Allergan, INC. | $14.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Naiditch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.